
Canaglifozin (Invokana, Janssen Pharmaceuticals) tablets, recently approved by the U.S. Food and Drug Administration for the improvement of glycemic control in adults with type 2 diabetes, is the first diabetes treatment approved in a new class of drugs known as sodium-glucose co-transporter 2 inhibitors.